Get the Stockscreener App
10.69
0.83%
-0.09
Pre-market:
10.79
0.10
+0.94%
10 X Genomics Inc stock is traded at $10.69, with a volume of 2.86M.
It is down -0.83% in the last 24 hours and down -28.73% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$10.78
Open:
$10.57
24h Volume:
2.86M
Relative Volume:
1.28
Market Cap:
$1.31B
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-5.2921
EPS:
-2.02
Net Cash Flow:
$-33.45M
1W Performance:
-1.93%
1M Performance:
-28.73%
6M Performance:
-54.22%
1Y Performance:
-77.08%
1-Day Range:
$10.40
$10.80
1-Week Range:
$10.40
$11.89
52-Week Range:
$10.40
$46.86
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
10.69 | 1.31B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
224.14 | 36.39B | 2.66B | 665.91M | 1.08B | 4.05 |
|
SOLV
Solventum Corp
|
79.75 | 13.78B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
70.50 | 13.23B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
56.18 | 9.67B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
109.76 | 9.51B | 1.15B | 96.70M | -161.99M | 1.09 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
ARK Investment Management LLC Purchases 1,193,712 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
SVB Wealth LLC Acquires Shares of 522,609 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Ieq Capital LLC Purchases 50,722 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
ING Groep NV Acquires New Shares in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics, Inc. (NASDAQ:TXG) CEO Sells $56,368.44 in Stock - MarketBeat
Director of 10x Genomics Picks Up 184% More Stock - Simply Wall St
Oxford Nanopore Expands Compatibility With 10x Genomics To Unlock Deeper Insights in Single-Cell Transcriptomics - Technology Networks
Insider Buying: 10x Genomics, Inc. (NASDAQ:TXG) Director Buys 40,000 Shares of Stock - MarketBeat
10x genomics’ president sells $50,602 in stock - Investing.com India
10x genomics CEO Serge Saxonov sells $56,346 in stock By Investing.com - Investing.com South Africa
10x genomics CEO Serge Saxonov sells $56,346 in stock - Investing.com
10x genomics director Alan Mateo acquires $445,572 in stock - Investing.com
10x Genomics Director Mateo Alan Acquires 40,000 Shares - TradingView
Alberta Investment Management Corp Takes $3.21 Million Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis – Company AnnouncementFT.com - Financial Times
Harvard, 10x Genomics Settle Patent Dispute With Vizgen - Harvard Crimson
10x Genomics, Inc. (NASDAQ:TXG) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
William Blair Estimates 10x Genomics Q3 Earnings - MarketBeat
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference - The Eastern Progress Online
10x Genomics, Inc. (NASDAQ:TXG) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Q1 EPS Estimates for 10x Genomics Lowered by Leerink Partnrs - MarketBeat
10x Genomics (NASDAQ:TXG) Lowered to "Hold" Rating by Leerink Partnrs - MarketBeat
Analysts Offer Predictions for 10x Genomics Q1 Earnings - MarketBeat
10x Genomics (NASDAQ:TXG) Stock Price Up 8.3%Here's What Happened - MarketBeat
Citigroup Has Lowered Expectations for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat
10x Genomics (NASDAQ:TXG) Price Target Cut to $12.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
10x Genomics' SWOT analysis: genomics firm faces NIH funding headwinds - Investing.com
10x Genomics (NASDAQ:TXG) Shares Gap Down on Disappointing Earnings - MarketBeat
10x Genomics (NASDAQ:TXG) Posts Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Entropy Technologies LP Purchases 27,844 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (NASDAQ:TXG) Price Target Cut to $26.00 by Analysts at Morgan Stanley - MarketBeat
Barclays Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat
Canaccord Genuity Group Has Lowered Expectations for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat
UBS Group Cuts 10x Genomics (NASDAQ:TXG) Price Target to $14.00 - MarketBeat
10x Genomics (NASDAQ:TXG) Rating Lowered to "Market Perform" at Leerink Partners - MarketBeat
10x Genomics falls on quarterly EPS miss, 2025 revenue guidance concern - MSN
Morgan Stanley Trims Price Target on 10x Genomics to $26 From $28, Keeps Overweight Rating - Marketscreener.com
10x Genomics Inc Reports Q4 Revenue of $165M, Beating Estimates; EPS of -$0.40 Misses Expectations - GuruFocus.com
Sumitomo Mitsui Trust Group Inc. Has $82.05 Million Stock Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10X Genomics Earnings Call: Innovations Amidst Revenue Challenges - TipRanks
10x Genomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025 - Victoria Advocate
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties - Benzinga
10X Genomics stock plunges to 52-week low of $11.89 - MSN
10x Genomics, Inc. Provides Earnings Guidance for the Year 2025 -February 12, 2025 at 04:05 pm EST - Marketscreener.com
10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Call Transcript - MSN
UBS Adjusts Price Target on 10x Genomics to $14 From $20, Keeps Neutral Rating -February 13, 2025 at 10:09 am EST - Marketscreener.com
10x Genomics Shares Tumble on Fear Over Cuts to NIH - MSN
10x Genomics (NASDAQ:TXG) Reaches New 12-Month Low Following Analyst Downgrade - MarketBeat
Leerink Partners Downgrades 10x Genomics to Market Perform From Outperform, Adjusts Price Target to $12 From $25 - Marketscreener.com
10x Genomics, Inc. SEC 10-K Report - TradingView
10x Genomics revenue increases 10% to USD 165M in Q4 2024 - Medical Buyer
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):